(Q33370786)

English

Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Alan Rodney

1

1 reference

Europe PubMed Central

26 July 2017

Pauline Dieringer

2

1 reference

Europe PubMed Central

26 July 2017

Paul Mathew

3

1 reference

Europe PubMed Central

26 July 2017

Eric Jonasch

4

1 reference

Europe PubMed Central

26 July 2017

Nizar Tannir

5

1 reference

Europe PubMed Central

26 July 2017

Lance C Pagliaro

6

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

1 May 2006

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

106

1 reference

Europe PubMed Central

26 July 2017

10

1 reference

Europe PubMed Central

26 July 2017

2143-2147

1 reference

Europe PubMed Central

26 July 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

An adverse interaction between warfarin and capecitabine: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21894

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21894

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33370786&oldid=1980487731"